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Background: With the increasing resistance of malaria parasites to available drugs, there is an urgent demand to
develop new anti-malarial drugs. Calpain inhibitor, ALLN, is proposed to inhibit parasite proliferation by suppressing
haemoglobin degradation. This provides Plasmodium calpain as a potential target for drug development. Pf-calpain,
a cysteine protease of Plasmodium falciparum, belongs to calpain-7 family, which is an atypical calpain not
harboring Ca2+-binding regulatory motifs. In this present study, in order to establish the screening system for
Pf-calpain specific inhibitors, the active form of Pf-calpain was first identified.
Methods: Recombinant Pf-calpain including catalytic subdomain IIa (rPfcal-IIa) was heterologously expressed and
purified. Enzymatic activity was determined by both fluorogenic substrate assay and gelatin zymography. Molecular
homology modeling was carried out to address the activation mode of Pf-calpain in the aspect of structural moiety.
Results: Based on the measurement of enzymatic activity and protease inhibitor assay, it was found that the active
form of Pf-calpain only contains the catalytic subdomain IIa, suggesting that Pf-calpain may function as a
monomeric form. The sequence prediction indicates that the catalytic subdomain IIa contains all amino acid
residues necessary for catalytic triad (Cys-His-Asn) formation. Molecular modeling suggests that the Pf-calpain
subdomain IIa makes an active site, holding the catalytic triad residues in their appropriate orientation for catalysis.
The mutation analysis further supports that those amino acid residues are functional and have enzymatic activity.
Conclusion: The identified active form of Pf-calpain could be utilized to establish high-throughput screening
system for Pf-calpain inhibitors. Due to its unique monomeric structural property, Pf-calpain could be served as a
novel anti-malarial drug target, which has a high specificity for malaria parasite. In addition, the monomeric form of
enzyme may contribute to relatively simple synthesis of selective inhibitors.
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reproduction in any medium, provided the orone million deaths were reported in 2010 [1]. Most deaths
by malaria are caused by Plasmodium falciparum, one of
the five species of human infectious malaria parasites, and
malaria is related to the distribution of Anopheles mosqui-
toes [2]. Unfortunately, the increasing resistance of malaria
parasites to available drugs has being reported [3,4]. There-
fore, there is a need to develop new anti-malarial drugs.
Plasmodium falciparum invades erythrocytes and
consumes the available haemoglobin as a means to
obtain nutrients during growth and maturation [5].
Many Plasmodium proteases appear to play key roles. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an erythrocyte, 2) degradation of haemoglobin, and 3)
rupture of erythrocytes. The degradation of haemoglobin
occurs in the acidic food vacuole (FV) formed by the para-
site in an erythrocyte, and up to 80% of haemoglobin is
consumed by malarial parasites [2,6]. In P. falciparum,
three different classes of proteases are mainly responsible
for the haemoglobin degradation; they include aspartic
proteases (plasmepsin I, II, IV and HAP), cysteine proteases
(falcipain-1, -2 and −3) and the metalloprotease (falcilysin)
[6-9]. Several exopeptidases such as dipeptidyl aminopepti-
dase 1 (DPAP1) and three metallo-aminopeptidases (A-M1,
APP and LAP) have also essential roles in haemoglobin
degradation [10-12]. Plasmepsin is known to be synthesized
in an inactive precursor form (membrane-bound proplas-
mepsin), and to be processed to mature form by mature
plasmepsin and falcipain, a cysteine protease [13,14]. Thus,
an aspartic protease inhibitor, Pepstatin A has been known
to block the processing of plasmepsin [5,6,14,15]. Since
Plasmodium plasmepsin and falcipain are involved in
haemoglobin degradation, which is necessary for parasite
proliferation in the host, they have been targeted for devel-
opment of anti-malarial drugs for decades [5,16-19]. How-
ever, plasmepsin activation does not seem to be completely
blocked by inhibitors of aspartic proteases and/or cysteine
proteases [5,20]. Recently, ALLN, a calpain inhibitor has
been proposed to have the inhibitory effect of plasmepsin
and falcipain [14,15]. Although its antimalarial activity is
likely due primarily to the inhibition of falcipain, it still
opens the possibility that calpain could be the one of the
mediators for haemoglobin degradation and, thereby, a po-
tential anti-malarial drug target.
Calpain is a cytoplasmic Ca2+-dependent, non-lysosomal
cysteine protease that is ubiquitously expressed in mam-
mals and many other organisms [13]. The P. falciparum
genome encodes a single calpain homologue, although no
biochemical data are available and it is not clear whether
the calpain is expressed or catalytically active in any para-
sitic stage [8]. The P. falciparum calpain (Pf-calpain) gene
differs significantly from those found in vertebrates to date
[21]. A putative calpain (MAL13P1.310) in P. falciparum
has high sequence similarity to Caenorhabditis elegans
calpain-7 [22-24]. They belong to a monophyletic group of
calpain-7, which might have contributed to an alternative
Ca2+-independent calpain activity [22]. Pf-calpain consists
of a central catalytic domain II (subdomain IIa and IIb)
and a C-terminal catalytic domain III. This domain com-
position is a distinct type that is not common to any other
types of calpain classes [24]. Pf-calpain was believed to be
an essential mediator of merozoite invasion, based on the
observation that a calpain inhibitor blocked invasion [25].
As the parasite progresses from trophozoite to schizont
stage, there is a 30-fold increase in the level of calpain tran-
scription [22].Based on reports, Pf-calpain seems to play a role in
haemoglobin degradation along with plasmepsin and
falcipain [14,15,26]. However, no direct evidence was
proposed that Pf-calpain participates in haemoglobin
degradation and ALLN indeed acts against this enzyme.
Thus, in this study, the active form of Pf-calpain was
investigated in the first place to check its enzymatic ac-
tivity and inhibition by ALLN. This active Pf-calpain was
further utilized to establish the high-throughput screen-
ing system for Pf-calpain inhibitors. Results suggest that
Pf-calpain is active only with catalytic subdomain IIa,
resulting in a monomeric form of enzyme. In addition,
the enzymatic activity of Pf-calapin was efficiently inhib-
ited by ALLN treatment. The monomeric structure of
Pf-calpain is considerably distinct from mammalian typ-
ical calpains and, thereby, Pf-calpain could serve as a tar-
get to develop parasite specific anti-malarial drugs. In
addition, the monomeric structure might accelerate drug
development by simplifying the synthesis steps of Pf-cal-
pain selective inhibitors.
Methods
Construction of recombinant calpains and point-mutated
calpains
The calpain genes were amplified using full length DNA
isolated from P. falciparum strain FCR-3. The calpain
genes for recombinant proteins were amplified by PCR
using the following primers: rPfcal-IIa; forward (5′-CGG
GAT CCC GGA ATG GGT AAA AGC AAA GAA CGT
AAA GGT-3′) and reverse (5′-CCG CTC GAG CGG
CTT TGT GTC CTC TAC AAA TTC AAC ACT GTT-
3′), rPfcal-IIb; forward (5′-CGG GAT CCC AAC GGG
TCA GTG GAT AAT TAT AGT GAT TTG-3′) and re-
verse (5′-CCG CTC GAG CGG ATC CAC ATT ATT
CAC ATT ATC CAC ATT ATC CAC-3′), rPfcal-IIab; for-
ward (5′-CGG GAT CCC GGA ATG GGT AAA AGC
AAA GAA CGT AAA GGT-3′) and reverse (5′-CCG
CTC GAG CGG ATC CAC ATT ATT CAC ATT ATC
CAC ATT ATC CAC-3′). The forward primers contained
BamHI site (in italics) and reverse primers contained XhoI
site (in italics) at their respective 5′-end. The PCR product
was cloned into the pGEM-T easy vector and digested
with BamHI and XhoI (New England BioLabs Inc., USA).
The calpain gene was ligated into pET21b(+) vector
(Novagen, USA) following its digestion with BamHI and
XhoI. The resultant pET21b: rPfcal-IIa plasmid was fur-
ther used as a parent construct for alanine-substitution
mutants. Alanine-substitution mutants at appropriate
positions of rPfcal-IIa were constructed using overlapping
PCR. To generate recombinant baculoviruses harboring
calpain genes, wild type and mutant calpain genes were
amplified by PCR using pET21b::rPfcal-IIa and pET21b::
rPfcal-IIa(HN) plasmid as parent constructs. The follow-
ing primers were used to construct: forward (5′-AT CAC
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(5′-G GGT ACC CCG ATC TGC AGT ATT CAC
ATT-3′). All primers contained BamHI or PstI re-
striction sites (shown as italic) for ligation to the
pFastBac HTA-M vector, kindly provided by Dr. JM
Yang in Sogang University, Korea.
Expression and purification of recombinant calpain
proteins
Bacterial system
The recombinant constructs was transformed into
Escherichia coli BL21 (DE3) cells. Induction was per-
formed with 1 mM isopropyl-β-D-thiogalactopyranoside
(IPTG) for four hours. Cells were harvested by centrifu-
gation and resuspended in 6 M Gu-HCl, 0.1 M sodium
phosphate buffer, 0.01 M Tris-Cl, pH 8.0 for 60 min.
The cell lysate was centrifuged and the supernatant was
incubated with the 50% Ni-NTA slurry for 60 min at
room temperature. The protein-bound resin was loaded
onto a column and washed twice with 4 ml of 8 M Urea,
0.1 M sodium phosphate buffer, 0.01 M Tris-Cl, pH 6.3.
The bound proteins were eluted with 8 M Urea, 0.1 M
sodium phosphate buffer, 0.01 M Tris-Cl, pH 5.9 and
continuously with 8 M Urea, 0.1 M sodium phosphate
buffer, 0.01 M Tris-Cl, pH 4.5. The eluted proteins were
quantified using the Bradford protein assay (Bio-Rad,
USA) and analysed by SDS-PAGE and Western blot.
rPf-calpain proteins were processed for refolding by
two-step dialysis in 0.01 M Tri-HCl, pH 7.5.
Insect cell system
The recombinant pFastBac HTA-M plasmids were trans-
fected into E. coli DH10Bac cells (Invitrogen, USA) to
induce the transposition of insert into baculoviral shuttle
vector. The resultant recombinant baculoviruses were
transfected to Sf9 cells (Invitrogen, USA) treated with
VivaMagicTM Transfection Reagent (Vivagen, Korea)
and incubated for three to five days (P1 viral stock).
Generated P1 viral stock was infected to Sf9 cells and
incubated for two to four days (P2 viral stock). The same
procedure was carried out to generate P3 viral stock.
The thirdly propagated baculoviruses were infected into
High Five cells (Invitrogen, USA) and incubated for five
to seven days. Cell supernatant containing expressed
recombinant proteins was collected, equilibrated, and fil-
tered. The equilibrated culture supernatant was incu-
bated with IgG Sepharose resin (GE Healthcare Life
Science, USA) for 30–60 min at 4°C with agitation. The
protein-bound resin was loaded into a column and
washed several times with 10X volumes of cold equilib-
rium buffer (10 mM sodium phosphate, 150 mM NaCl,
pH 8.0). The bound proteins were eluted with 100 mM
Glycine and 500 mM NaCl, pH 2.7 and instantly neu-
tralized with 2 M Tris-Cl buffer (pH 8.8). The elutedproteins were then dialysed in in cold PBS buffer, pH 8.5
at 4°C and concentrated with centrifugal filter device
(Amicon, Millipore, USA). Quantified proteins were
used for SDS-PAGE, Western blot analysis, and the
measurement of enzymatic activity.
Detection of endogenous and recombinant calpain
proteins
To confirm the presence of endogenous and recombinant
calpain proteins, Western blot analysis was performed.
Electrophoresed polyacrylamide gel was transferred onto a
nitrocellulose membrane (Hybond-ECL, Amersham
Bioscience, USA). The membrane was blocked with
5% skim milk and incubated either with a polyclonal
anti-His antibody (1:5,000 dilution) or an anti-Pf-cal-
pain antibody (anti-Pf-CapnA; AbFrontier, Korea)
(1:2,000 dilution) generated from previous study [27]
for two hours at room temperature. The blot was
further incubated with goat anti-mouse conjugated-
HRP antibodies for one hour (1:5,000 dilution).
Measurement of calpain activity using the fluorogenic
substrate assay
This assay was performed with Succinyl-Leu-Leu-Val-
Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) sub-
strate according to Debiasi et al. [28]. Recombinant
Pf-calpains were incubated with 20 μM Suc-LLVY-AMC
in a total volume of 200 μl with 100 mM Tris–HCl pH
7.5, 1 mM DTT for one hour at 37°C. For the inhibition
assay, 100 μM protease inhibitors were pre-incubated
with rPf-calpains for one hour at 37°C before adding
substrate. The fluorescence of AMC (aminomethylcou-
marin) was measured in one hour after the addition of
the substrates using a fluorometer (Infinite F200, Tecan,
Switzerland) with excitation at 360 nm and emission at
460 nm. The pH-optimum of rPf-calpains was tested
using this fluorogenic-substrate assay at various pH con-
ditions ranging from pH 4.5 to pH 9.5: 100 mM sodium
acetate buffer was used for pH 4.5 or pH 5.5 conditions,
and 100 mM Tris–HCl buffer was used for pH 6.5, pH
7.5, pH 8.5 and pH 9.5.
Measurement of calpain activity using gelatin
zymography
SDS-PAGE was performed using 10% polyacrylamide gels
containing 0.1% gelatin as a copolymerized substrate under
non-reducing conditions. The protein samples were pre-
pared by mixing with Tris-glycine-SDS sample buffer with-
out 2-mercaptoethanol for 10 min at room temperature.
Following protein separation, in order to remove SDS, the
gel was incubated in 2.5% Triton X-100 solution with vigor-
ous agitation for one hour at room temperature, and then
incubated in zymogram developing buffer containing 50
mM Tris–HCl, 0.2 M NaCl, 5 mM CaCl2 and 2.5% Triton
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protease inhibitors were diluted in zymogram developing
buffer. Finally, the gel was stained with Coomassie blue
R-250 and followed by destaining. The proteolytic activity
of rPf-calpains was determined by observing clear zones on
SDS gels.
Homology modeling of Pf-calpain subdomain IIa
The primary sequence of Pf-calpain (accession: HQ386136),
which was determined in previous report [27], was used as
a query to search the most appropriate template for hom-
ology modeling. Using the non-redundant (nr) protein
sequence database taken from the National Center for
Biotechnology Information [29], BLAST (basic local align-
ment search tool) [30] search was performed. Among the
searched proteins whose X-ray crystal structures are avail-
able, human calpain 8 (Hs-calpain 8) showed the highest
sequence identity with Pf-calpain, and its active form com-
plexed with leupeptin and Ca2+ ions was selected as a tem-
plate (2NQA.pdb).
Based on the primary sequences of Pf-calpain and the
selected template Hs-calpain 8, multiple sequence align-
ment was performed with CLUSTAL W2 which uses a
progressive pairwise alignment algorithm [31]. Since the
highly conserved cysteine, histidine, and asparagine resi-
dues are reported to form the catalytic triad in the cata-
lytic site of calpain [27], these catalytic triads of Pf-calpain
and Hs-calpain 8 were focused on matching. Initially,
sequences of Pf-calpain and Hs-calpain 8 were aligned,
but a reasonable result with well-matched catalytic triads
was not obtained. Therefore, sequence alignment in two
steps was carried out using Hs-calpain 7 as a reference,
because it is reported that the Pf-calpain genome exhibits
high sequence similarity to C. elegans calpain 7 [22], and
the BLAST search result showed that Hs-calpain 7 pos-
sessed high sequence identity to Pf-calpain. Firstly, two
sets of sequences were aligned, one contains Pf-calpain,
Pv-calpain (accession: HQ386136), and Hs-calpain 7 (ac-
cession: NP055111); and the other consists of Hs-calpain
7 and Hs-calpain 8 (PDB id: 2NQA). Then, the sequences
of Pf-calpain and Hs-calpain 8 were manually aligned
using the aligned sequence of Hs-calpain 7 as a reference.
Using the multiple sequence alignment, the homology
model of Pf-calpain was built by MODELER v.9.4 pro-
gram in Discovery Studio v.3.5 (Accelrys Software Inc.,
USA). The validity of the models and compatibility of
each amino acid residue in the given 3D environment
were checked by Verify Protein (Profiles-3D) protocol in
Discovery Studio (Additional file 1 and 2). Among the
resulting 50 models, the most appropriate model, i.e.,
one with the low probability density function (PDF) total
energy, high verify score, and adequate orientation of the
catalytic triad residues, was chosen for the loop refine-
ment process. All hydrogen atoms were added to therefined model, and the protonation state of the ionizable
groups was chosen appropriate to pH 7.4 including the
protonated His1179 [32]. Then, the model was further
refined by the 1000 ps molecular dynamics (MD) simu-
lation and energy minimization with CHARMm force
field. During the simulations, the implicit solvent model
was applied using generalized born with molecular vol-
ume (GBMV) method [33]. The final model was evaluated
by verify protein (Profiles-3D) and ERRAT score from the
structure analysis and verification server (SAVES) [34].
Docking of ALLN onto the active site of Pf-calpain
subdomain IIa
The 3D structure of ALLN was generated with Concord
and energy minimized using MMFF94s force field and
MMFF94 charge until the rms of Powell gradient was
0.05 kcal/mol·Å in SYBYL v.8.1.1 (Tripos Int., USA).
The docking study on the minimized homology model of
Pf-calpain was carried out using GOLD v.5.1 (Cambridge
Crystallographic Data Centre, UK), which employs a gen-
etic algorithm (GA). The binding site was defined as 12 Å
around the sulphur atom of Cys1035, and the side chains
of Cys1035 and His1179 were set to be flexible with ‘crys-
tal mode’.
For the covalent docking, the hydrogen atom attached
to the sulphur atom of Cys1035 was removed, and the
hydrogen atom in the aldehyde group of ALLN was
replaced to sulfur. Then, the sulfur atoms of Cys1035
and ALLN were set as the protein link atom and ligand
link atom, respectively. The carbonyl oxygen of ALLN
and the delta-position hydrogen of His1179-imidazole
were constrained to form a hydrogen bonding inter-
action. GoldScore scoring function was used and other
parameters were set as defaults except that the number
of GA runs was 50. The resulting docked complexes
were energy minimized using the CHARMm force field
and the implicit solvent model, GBMV, until the rms of
conjugate gradient was lower than 0.0001 kcal/mol·Å.
Molecular dynamics simulation of Pf-calpain subdomain
IIa complexed with ALLN
Molecular dynamics (MD) simulation was performed by
the CHARMm program, implemented in Discovery Studio
v.3.5, with CHARMm force field and cff partial charge.
The complex structure of Pf-calpain and covalently-bound
ALLN was solvated by water molecules with orthothrom-
bic cell shape of the explicit periodic boundary model. The
solvated system was gently minimized with steepest des-
cent algorithm until the tolerance reached 0.1 kcal/mol·Å,
and further minimized by conjugate gradient algorithm
until the tolerance reached 0.0001 kcal/ mol·Å. The mini-
mized system was gradually heated to 300 K, and then, it
was followed by the equilibration step for 300 ps. Finally,
the production phase was carried out during 3000 ps using
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the integration time step of 1 fs was used, and the SHAKE
constraints were applied.
All computation calculations were undertaken on an
IntelW XeonTM Quad-core 2.5 GHz workstation with
Linux Cent OS release 5.5. Sequence alignment, hom-
ology modeling, loop refinement, energy minimization
and molecular dynamics were performed in Discovery
Studio v.3.5 (Accelrys Inc., USA). Figures are generated
by the SYBYL v.8.1.1 and PyMOL Molecular Graphics
System v.1.3.
Results
The catalytic domain IIa is sufficient for enzymatic activity
of Pf-calpain
To characterize the Plasmodium calpain protein, the full
length genomic Pf-calpain gene (6.2 kb) was firstly cloned
from P. falciparum FCR-3 strain (Figure 1A; Accession No.
HQ386136). Multiple alignments revealed that Pf-calpain
protein of P. falciparum FCR-3 strain (Accession No.
ADQ00190.1) is 98% identical to that of P. falciparum 3D7
strain (Accession No. ABR18792.1). As described elsewhereFigure 1 The enzymatically active form of Pf-calpain is identified. A) S
Pf-calpain constructs. Cys 1035, His 1371, and Asn 1391 were indicated in c
1179) and asparagine (Asn 1195) residues were shown in red. These residu
anti-Pfcalpain antibodies. Left, anti-PfCapnA antibody; Right, anti-PfCapnB a
anti-Pf-calpain antibodies. C) Calpain enzymatic activity measured by the flu
gelatin zymography.[22,23], Pf-calpain belongs to atypical calpain family, and
has the highest similarity with mammalian calpain-7
(Accession No. NP_055111) and C. elegans calpain-7
(Accession No. NP_497964). They do not have regulatory
subunits and thus they are considered to have Ca2+-
independent calpain activity. However, crucial amino acid
residues are well conserved in the catalytic subdomain IIa
(cysteine) and IIb (histidine and asparagine).
To address the activation mode of Pf-calpain, three
kinds of recombinant calpain genes were designed
based on the full length genomic Pf-calpain gene (6.2
kb). Each recombinant Pf-calpain includes catalytic
subdomain IIa (rPfcal-IIa), catalytic subdomain IIb
(rPfcal-IIb), and catalytic subdomain IIab (rPfcal-IIab),
respectively. Recombinant proteins were successfully
expressed and purified in bacterial system. The pro-
teins were confirmed with western blot analysis using
anti-PfCapnA and anti-PfCapnB antibodies, which can
specifically recognize Pf-calpain. The predicted size of
recombinant proteins was approximately 50 kDa for
rPfcal-IIa, 40 kDa for rPfcal-IIb, and 90 kDa for rPfcal-
IIab (Figure 1B).chematic diagram of the full-length Pf-calpain and three recombinant
atalytic subdomain IIa and IIb, respectively. The predicted histidine (His
es were further analysed. Black boxes indicate the recognition sites of
ntibody. B) Western blot of purified recombinant Pf-calpains using an
orogenic substrate assay. D) Calpain enzymatic activity measured by
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mined either with the fluorogenic substrate assay using
Suc-LLVY-AMC substrate or with gelatin zymography.
Interestingly and very surprisingly, recombinant protein
having only catalytic subdomain IIa (rPfcal-IIa) displayed
the highest enzymatic activity compared to the others
(Figure 1C and 1D). The fluorescence of substrates was
apparently increased and the proteolytic activity against
gelatin was obviously seen on SDS gel. However, rPfcal-
IIb did not exhibit any enzymatic activity in both assays
and rPfcal-IIab showed relatively lower enzymatic activ-
ity. Thus, rPfcal-IIa protein was further analysed.
Very interestingly, the protein size of rPfcal-IIa was
nearly identical to that of endogenous calpain fragment,
which was detected from P. falciparum whole protein
extracts (Figure 2A). Although the entire Pf-calpain pro-
tein is supposed to be expressed with approximately 225
kDa, the 46 kDa calpain fragment was only detectedFigure 2 The catalytic subdomain IIa is sufficient to have enzymatic a
endogenous Pf-calpain were confirmed by Western blot analysis using anti
size marker; lane 1, un-induced E. coli cell lysate; lane 2, purified rPfcal-IIa; P
rPfcal-IIa was assessed by fluorogenic substrate assay. The activity of rPfcal-
zymography and D) the fluorogenic substrate assay. C) The proteolytic acti
mean ± S.D. Statistical analysis was performed using the student’s t-test. **from whole lysate of parasites with anti-Pf-calpain anti-
body. This indirectly suggests that the form of Pfcal-IIa
could be actually active Pf-calpain in vivo. However, it
cannot rule out the possibility of autolysis and/or deg-
radation of calpain protein during preparation.
The optimal pH condition for rPfcal-IIa activity was fur-
ther tested. The pH condition ranging from 4.5 to 9.5 was
used to elucidate the optimal pH of purified rPfcal-IIa pro-
tein (Figure 2B). As shown in Figure 2B, the fluorogenic
substrate assay revealed that rPfcal-IIa protein is the most
active at pH 7.5. Thus, pH 7.5 was used as the optimal pH
condition for the subsequent assays. Next, the enzymatic
activity of rPfcal-IIa protein was checked with the addition
of various protease inhibitors; ALLN as a calpain inhibitor,
E-64 as a common cysteine protease inhibitor, PMSF as a
serine protease inhibitor, and Pepstatin A as an aspartic
protease inhibitor. Both fluorogenic substrate assay and
gelatin zymography showed that the enzymatic activity ofctivity of Pf-calpain. A) Purified recombinant Pfcal-IIa (rPfcal-IIa) and
-PfCapnA antibody (α-Cal) and anti-poly-His Tag antibody (α-His). M,
f, protein extracts of P. falciparum. B) Effect of pH on the activity of
IIa and the effects of protease inhibitors were analysed by C) gelatin
vity is shown in clear zone on SDS gels. D) Data are presented as
p < 0.01.
Figure 3 Multiple sequence alignment of the catalytic subdomain IIa. Plasmodium falciparum (FCR-3) calpain (GenBank, ADQ00190.1), P.
falciparum (3D7) calpain (GenBank, ABR187921.1), Plasmodium vivax calpain (GenBank, EDL46679.1), and Homo sapiens calpain-7 (GenBank,
NP_055111) were aligned using Crystal W2 program. P. falciparum (FCR-3) calpain was 33.6% identical to H. sapiens calpain-7 and 73.5% identical
to P. vivax calpain. The predicted histidine (His 1179) and asparagine (Asn 1195) residues were shown in red with cysteine (Cys 1035).
Figure 4 Homology model of Pf-calpain subdomain IIa. A) Molecular surface of the model. Connolly surface was generated by MOLCAD and
colored by lipophilic potential (LP). B) The z-clipped surface of the model and its secondary structure with gray line ribbon representation. The
catalytic triad residues are represented as sticks, and the catalytic cleft is marked with the red box. Figure is generated by the SYBYL v.8.1.1.
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Figure 5 Comparison of the Pf-calpain model to the active and inactive forms of the typical calpain. A) Rat calpain 2 without Ca2+ ion
(1U5I.pdb). B) Rat calpain 2 complexed with Ca2+ ions (1MDW.pdb). C) The homology model of Pf-calpain subdomain IIa. Catalytic triad residues
are displayed in sticks and their residue numbers are marked. Figure is generated by the SYBYL v.8.1.1.
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E-64 (Figure 2C and 2D). These results confirmed that
rPfcal-IIa protein is indeed the active form of Pf-calpain
and thereby its activity is inhibited by a broad cysteine pro-
tease inhibitor, E-64. More interestingly, a calpain inhibitor,
ALLN could effectively inhibit Pf-calpain, supporting the
possibility that Pf-calpain may contribute to the inhibition
of malaria parasite proliferation under ALLN treatment.Pf-calpain may act in monomeric form
It has been well documented that the catalytic subdo-
main IIa and IIb play a key role for calpain enzymatic
activity because of catalytic triad formed among amino
acid residues in those subdomains [22,35]. In the pres-
ence of Ca2+, two catalytic subdomains become structurally
closer and thereby cysteine residue in the subdomain IIa
and histidine-asparagine residues in the subdomain IIb
form a functional catalytic site [35]. However, Pf-calpain is
considered to be Ca2+-independent. Furthermore, in this
study, it is shown that the catalytic subdomain IIa is suffi-
cient to have an enzymatic activity of calpain. Thus, the
next question addressed is how Pf-calpain becomes
active.First of all, the amino acid sequence of catalytic subdo-
main IIa was analysed. Multiple sequence alignment was
performed using the sequences of Pf-calpain, Pv-calpain
and Homo sapiens calpain-7 (Figure 3). Interestingly, it
was predicted that the catalytic subdomain IIa contains
plausible histidine (His1179) and asparagine (Asn1195)
residues necessary for forming catalytic triad. This may
explain how Pf-calpain is active without Ca2+ stimulation.
To test whether those histidine and asparagine residues
are functional or not, two different approaches were con-
ducted. One is molecular modeling and the other is mo-
lecular technique introducing mutations on those amino
acid residues.
Homology model of Pf-calpain subdomain IIa appears to
well construct the active site residues for catalysis
In order to predict the structure of Pf-calpain, homology
modelling study was conducted. The X-ray crystal struc-
ture of Hs-calpain 8 (PDB id: 2NQA) was selected as a
template, since it shows the minimum E-value at the
BLAST search of Pf-calpain sequence in the protein data
bank. The sequence identity and similarity between Pf-
calpain and Hs-calpain 8 are 16% and 31%, respectively.
Based on the multiple sequence alignment (Figure 3),
Figure 6 Refined model of Pf-calpain subdomain IIa covalently bound with ALLN. The secondary structure of Pf-calpain is displayed in grey
line ribbon. The catalytic triad residues, Cys1035, His1179, and Asn1195, are displayed in ball-and-stick with the carbon color of hotpink. ALLN,
covalently bound with Cys1035, was represented in ball-and-stick with the carbon color of hotpink, and its van der Waals surface was created by
MOLCAD. In the enlarged view, the Connolly surface of Pf-calpain is displayed in mesh, and z-clipped from back and forth for the visual
convenience. The molecular surfaces of the protein and ligand are colored by lipophilic potential (LP). Figure is generated by the PyMOL
Molecular Graphics System v.1.3.
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most reasonable model was refined by Loop Refinement
protocol in MODELER. The resulting model was further
refined by the molecular dynamics (MD) simulation and
energy minimization.
The overall topology of the Pf-calpain subdomain IIa
homology model shows a globular shape and the active site
is well constructed for the enzyme function (Figure 4). In
case of the typical calpains, the activation state is dependent
on the Ca2+ binding [36]. In the absence of Ca2+, the typical
calpains are inactive with their subdomains IIa and IIb dis-
tant to each other (Figure 5A). Upon the Ca2+ binding, the
subdomains IIa and IIb become quite closer and make the
catalytic triad properly oriented for catalysis (Figure 5B).
Interestingly, the homology model of Pf-calpain subdomain
IIa consists of two lobes, and it forms the active site con-
taining the plausible catalytic triad residues, Cys1035,
His1179, and Asn1195, close to one another (Figure 5C).
The first lobe (residues from Gly990 to Ile1156) of the
model is very similar to the catalytic subdomain IIa of the
typical calpain structures. The catalytic Cys1035 is located
in this lobe, and its side chain faces toward the cleft region
between the two lobes. In addition, Gln1029 interacts with
the backbone NH of Cys1035, forming the oxyanion hole,
which is reported to stabilize the catalytic intermediate
[32]. The second lobe (residues from Pro1157 to Asn1218)
contains His1179 and Asn1195, which are properly posi-
tioned to make the hydrogen bond network with Cys1035,reflecting their roles as the catalytic triad. Unlike the typ-
ical calpains, Pf-calpain is sufficiently enough to function
with the subdomain IIa only, and this result could explain
why it has catalytic activity independent to Ca2+ binding.
ALLN showed the inhibitory activity onto Pf-calpain
[14,15,26]. To predict its binding mode, the covalent
docking of ALLN was performed into the active site of
Pf-calpain model using GOLD program. The complex
structure was further refined by molecular dynamics
(MD) simulation in the explicitly solvated system. ALLN
was nicely occupied the cleft between the two lobes of
Pf-calpain and made the covalent bond with catalytic
Cys1035 (Figure 6). It also formed the H-bonding inter-
actions with Ser1143, Thr1178, and His1179, explaining
its good inhibitory activity onto Pf-calpain.
Point mutation study confirmed that the catalytic triad
may be formed in the catalytic subdomain IIa
Plausible histidine and asparagine residues in the cata-
lytic subdomain IIa were point mutated to see their
functionality. Two amino acid residues were substituted
by alanine (Figure 7A). The recombinant Pfcal-IIa gene
(rPfcal-IIa) and the mutated recombinant Pfcal-IIa gene
(rPfcal-IIa(HN)) were cloned and successfully expressed
in insect cell system (Figure 7B). Purified recombinant
proteins were tested for their enzymatic activity using
the fluorogenic substrate assay. Intriguingly, the mutated
rPfcal-IIa proteins (rPfcal-IIa(HN)) did not show any
Figure 7 The predicted histidine and asparagine residues are functional. A) Histidine and asparagine residues were alanine-substituted and
confirmed by sequencing. Targeted amino acids were underlined in chromatogram. B) Both wild-type form of rPfcal-IIa (WT) and mutant form of
rPfcal-IIa (MT) were expressed in the baculovirus system. Purified proteins were confirmed by Western blot using anti-PfCapnA antibody. C) The
enzymatic activity was measured by fluorogenic substrate assay. The mutations in predicted histidine and asparagine residues completely
disrupted enzymatic activity of rPfcal-IIa.
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(Figure 7C). The enzymatic activity was dramatically
reduced with the mutations in two amino acid residues.
These suggest that two amino acid residues in the cata-
lytic subdomain IIa are actually functional. This supports
the possibility that Pf-calpain may act in monomeric
form.
Discussion
With the increasing resistance of malaria parasites to
available drugs [3,4], there is a need to develop new anti-
malarial drugs. Although Plasmodium plasmepsin and
falcipain have been targeted for developing anti-malarial
drugs [5,16-19], it has been revealed that a common
aspartic proteases inhibitor and cysteine proteases inhi-
bitor cannot completely inhibit plasmepsin and falcipain
activity [5,20]. Meanwhile, ALLN, a calpain inhibitor has
been proposed to inhibit plasmepsin and falcipain [14,15].
Nonetheless, it is still viable to reason the probability that
calpain could be one of the mediators for haemoglobin deg-
radation [26]. Pf-calpain was identified from P. falciparum
FCR-3 strain with high identity to a putative Pf-calpain pre-
viously reported (3D7 strain, MAL13P1.310) [24,27]. The
catalytic domain II of newly isolated Pf-calpain has highsequence similarity to the calpain-7 family that contains
three active sites (Cys1035, His1371 and Asn1391). These
three sites constitute a cleft crucial for a catalytic activity
[22,23]. A Cys-His-Asn triad, with a high degree of identity
to human calpains is observed in its vicinity, reflecting
stringent functional and mechanistic conservation [22].
In this study, for the first time, the active form of Pf-
calpain was identified. Surprisingly, the active form of
Pf-calpain was revealed to consist only of the catalytic
subdomain IIa. This result was unexpected because the
catalytic subdomain IIa is supposed to have an incom-
plete Cys-His-Asn triad structure. However, all evidences
resolved in this study propose that Pf-calpain is sufficiently
active only with the catalytic subdomain IIa; 1) endogen-
ous Pf-calpain was detected from P. falciparum whole
extracts with the similar size to rPfcal-IIa; 2) rPfcal-IIa
showed the strongest enzymatic activity and this activity
was effectively inhibited by E-64 and ALLN; 3) the cata-
lytic subdomain IIa is predicted to have plausible histidine
and asparagine residues; 4) the mutations of those amino
acid residues completely disrupted Pf-calpain activity; and
5) finally, molecular modeling study predicted the molecu-
lar structure of Pf-calpain subdomain IIa, and it supports
that Cys1035, His1179, and Asn1195 residues in
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forming the catalytic triad with the appropriate orientation
for catalysis.
Pf-calpain seems to be activated by different way from
mammalian typical calpains. Since Pf-calpain does not
have regulatory subunits (domain V and VI), it may
function as a monomeric form. In addition, since Pf-
calpain does not have domains responsible for Ca2+
binding (domain IV in the catalytic subunit and domain
VI in the regulatory subunit), Ca2+ may not contribute
to the conformational change leading to the closer
positioning of catalytic subdomain IIa and IIb, which
have important amino acid residues necessary for cata-
lytic triad formation. These results propose the possible
activation mode of Pf-calpain. The catalytic subdomain
IIa has all three functional amino acid residues, and the
homology model of Pf-calpain showed that the catalytic
site can be formed with subdomain IIa only, reflecting
the catalytic activity independent to Ca2+ binding. Al-
though Hs-calpain 8 was utilized as a template to ana-
lyse homology model, Pf-calpain possesses only 16%
identity with Hs-calpain 8, providing Pf-calpain as
a parasite-specific target. Furthermore, the distinct
monomeric structure of calpain is highly specific for
malaria parasite. Thus, Pf-calpain could be served as a
novel target to develop parasite specific anti-malarial
drugs. In that point of view, the identification of enzy-
matically active Pf-calpain might be the starting point
to establish high-throughput screening system for Pf-
calpain-based drug development. In addition, the mono-
meric structure of Pf-calpain may provide tremendous
advantages to synthesize candidate compounds by simpli-
fying the synthesis steps.
Recent reports revealed that calpain may localize in
nucleolus and/or cytoplasm [27,37]. The transcription
level of calpain is highly expressed in schizont stage
[22], but anti-Pf-calpain antibodies detect calpain ex-
pression throughout the developmental stages from
early ring to late schizont [27]. It has been involved
in cell cycle progression during trophozoite develop-
ment [24]. However, the biological functions of Pf-
calpain are still largely unknown. In this study,
biochemical and structural properties of Pf-calpain
was uncovered. The neutral Pf-calpain provokes a
critical question. How this neutral enzyme could be
involved in haemoglobin hydrolysis, if is the case? It
is well known that haemoglobin degradation occurs in
acidic food vacuole primarily by acidic proteases [5,6].
Thus, it is unclear yet whether Pf-calpain mediates
haemoglobin degradation or not. If it is involved in
haemoglobin metabolism, then it is also inconclusive
whether it is in a way through plasmepsin and
falcipain or in an independent way. Further functional
studies will be needed.Additional files
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